Werewolf Therapeutics, Inc.
HOWL
$0.7998
-$0.0702-8.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -0.53% | -1.17% | |||
| Gross Profit | 0.53% | 1.17% | |||
| SG&A Expenses | -28.76% | 73.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.58% | 18.83% | |||
| Operating Income | 11.58% | -18.83% | |||
| Income Before Tax | 11.33% | -22.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.33% | -22.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.33% | -22.35% | |||
| EBIT | 11.58% | -18.83% | |||
| EBITDA | 11.76% | -19.41% | |||
| EPS Basic | 12.03% | -20.24% | |||
| Normalized Basic EPS | 12.03% | -20.26% | |||
| EPS Diluted | 12.03% | -20.24% | |||
| Normalized Diluted EPS | 12.03% | -20.26% | |||
| Average Basic Shares Outstanding | 0.78% | 1.77% | |||
| Average Diluted Shares Outstanding | 0.78% | 1.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||